Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: A systematic literature review

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 327-338

  Colosia, Anna D ^a   Palencia, Roberto ^b   Khan, Shahnaz ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Blood pressure; Body mass index; Epidemiology; T2DM; Waist circumference

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE;

ARTICLE; ASIA; BLOOD PRESSURE REGULATION; BODY MASS; COMORBIDITY; EUROPE; GEOGRAPHIC DISTRIBUTION; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; SOUTH AMERICA; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

EID: 84884547666     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S51325     Document Type: Article

References (122)

1. Nakano S, Ito T, Furuya K, et al. Ambulatory blood pressure level rather than dipper/nondipper status predicts vascular events in type 2 diabetic subjects. Hypertens Res. 2004;27(9):647-656.
2. Salman RA, Al-Rubeaan KA. Incidence and risk factors of hypertension among Saudi type 2 diabetes adult patients: an 11-year prospective randomized study. J Diabetes Complications. 2009;23(2):95-101.
3. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49(8):1761-1769.
4. Anderson RJ, Bahn GD, Moritz TE, et al; VADT Study Group. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011;34(1):34-38.
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
6. Bakris GL, Weir MR, Shanifar S, et al; RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163(13):1555-1565.
7. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol. 2007;6:13.
8. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65-73.
9. Song SH, Hardisty CA. Type 2 diabetes mellitus: a high-risk condition for cardiovascular disease irrespective of the different degrees of obesity. QJM. 2008;101(11):875-879.
10. Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia. 2006;49(12):2859-2865.
11. Kim SK, Kim HJ, Ahn C W, et al. Hyperleptinemia as a robust risk factor of coronary artery disease and metabolic syndrome in type 2 diabetic patients. Endocr J. 2008;55(6):1085-1092.
12. Scott R, O'Brien R, Fulcher G, et al; Fenofbrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenof-brate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofbrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493-498.
13. Tseng CH, Chong CK, Tseng C P, Shau WY, Tai T Y. Hypertension is the most important component of metabolic syndrome in the association with ischemic heart disease in Taiwanese type 2 diabetic patients. Circ J. 2008;72(9):1419-1424.
14. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8-13.
15. World Health Organization (WHO). Cardiovascular diseases (CVDs) [web page on the Internet]. Fact sheet no 317. Geneva: WHO; 2012 [updated September]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed January 23, 2013.
16. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22): 2746-2753.
17. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-713.
18. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013;36 Suppl 1:S11-S66.
19. WHO. World Health Statistics 2012. Geneva: WHO; 2012. Available from: http://www.who.int/gho/publications/world_health_statistics/EN_WHS2012_Full.pdf. Accessed January 23, 2013.
20. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379. Erratum in: Diabetes Care. 2013;36(2):490.
21. Health and Environment Alliance (HEAL). Figures on Obesity and Diabetes in the European Union. Brussels: HEAL; nd. Available from: http://www.env-health.org/IMG/pdf/Obesity_and_diabetes_in_the_European_Union_to_partners_2_.pdf. Accessed February 14, 2013.
22. Romero CX, Romero TE, Shlay JC, Ogden LG, Dabelea D. Changing trends in the prevalence and disparities of obesity and other cardiovascular disease risk factors in three racial/ethnic groups of USA adults. Adv Prev Med. 2012;2012:172423.
23. Cook-Huynh M, Ansong D, Steckelberg RC, et al. Prevalence of hypertension and diabetes mellitus in adults from a rural community in Ghana. Ethn Dis. 2012;22(3):347-352.
24. Ford ES, Mokdad AH, Giles WH, Galuska DA, Serdula MK. Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors. Obes Res. 2005;13(1):118-122.
25. Shen J, Goyal A, Sperling L. The emerging epidemic of obesity, diabetes, and the metabolic syndrome in China. Cardiol Res Pract. 2012;2012:178675.
26. Keenan NL, Rosendorf KA; Centers for Disease Control and Prevention (CDC). Prevalence of hypertension and controlled hypertension - United States, 2005-2008. MMWR Surveill Summ. 2011;60 Suppl: 94-97.
27. CDC. Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004;53(45):1066-1068.
28. Tiptaradol S, Aekplakorn W. Prevalence, awareness, treatment and control of coexistence of diabetes and hypertension in thai population. Int J Hypertens. 2012;2012:386453.
29. Thomas MC, Atkins R. Assessment and management of hypertension in patients with type 2 diabetes. Intern Med J. 2009;39(3):143-149.
30. Chen XY, Thomas GN, Chen YK, Chan JC, Wong KS. Atherosclerotic vascular disease rather than metabolic syndrome predicts ischemic stroke in diabetic patients. Cerebrovasc Dis. 2010;30(4):374-379.
31. Kabakov E, Norymberg C, Osher E, et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J Cardiometab Syndr. 2006;1(2):95-101.
32. Koehler C, Ott P, Benke I, Hanefeld M; DIG Study Group. Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study. Horm Metab Res. 2007;39(9): 632-635.
33. Lu B, Yang Y, Song X, et al. An evaluation of the International Diabetes Federation definition of metabolic syndrome in Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus. Metabolism. 2006;55(8):1088-1096.
34. Marchesini G, Forlani G, Cerrelli F, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004;21(4):383-387.
35. Relimpio F, Martinez-Brocca MA, Leal-Cerro A, et al. Variability in the presence of the metabolic syndrome in Type 2 diabetic patients attending a diabetes clinic. Influences of age and gender. Diabetes Res Clin Pract. 2004;65(2):135-142.
36. Viswanathan V, Snehalatha C, Kumutha R, Nair BM, Ramachandran A. Impact of Joint National Committee VII recommendations on diabetic microvascular complications. J Assoc Physicians India. 2004;52: 873-876.
37. Makuyana D, Gomo Z, Munyombwe T, Matenga JA, Hakim JG. Metabolic syndrome disorders in urban black Zimbabweans with type 2 Diabetes mellitus. Cent Afr J Med. 2004;50(3-4):24-29.
38. Choukem SP, Kengne AP, Dehayem YM, Simo NL, Mbanya JC. Hypertension in people with diabetes in sub-Saharan Africa: revealing the hidden face of the iceberg. Diabetes Res Clin Pract. 2007;77(2): 293-299.
39. Alebiosu CO, Odusan BO. Metabolic syndrome in subjects with type-2 diabetes mellitus. J Natl Med Assoc. 2004;96(6):817-821.
40. Puepet FH, Agaba EI, Chuhwak EK. Some metabolic abnormalities in type 2 diabetic patients in Jos, north central Nigeria. Niger J Med. 2003;12(4):193-197.
41. Ogbera AO, Azenabor AO. Hyperuricaemia and the metabolic syndrome in type 2 DM. Diabetol Metab Syndr. 2010;2:24.
42. Ikem RT, Akinola NO, Balogun MO, Ohwovoriole AE, Akinsola A. What does the presence of hypertension portend in the Nigerian with non insulin dependent diabetes mellitus. West Afr J Med. 2001;20(2): 127-130.
43. Isezuo SA, Ezunu E. Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients. J Natl Med Assoc. 2005;97(4):557-563.
44. Bunnag P, Plengvidhya N, Deerochanawong C, et al. Thailand diabetes registry project: prevalence of hypertension, treatment and control of blood pressure in hypertensive adults with type 2 diabetes. J Med Assoc Thai. 2006;89 Suppl 1:S72-S77.
45. El-Hazmi MA, Warsy AS. Association of hypertension and non-insulin-dependent diabetes mellitus in the Saudi population. Ann Saudi Med. 2001;21(1-2):5-8.
46. Alwakeel JS, Sulimani R, Al-Asaad H, et al. Diabetes complications in 1952 type 2 diabetes mellitus patients managed in a single institution in Saudi Arabia. Ann Saudi Med. 2008;28(4):260-266.
47. Kim WY, Kim JE, Choi YJ, Huh KB. Nutritional risk and metabolic syndrome in Korean type 2 diabetes mellitus. Asia Pac J Clin Nutr. 2008;17 Suppl 1:47-51.
48. Mubarak FM, Froelicher ES, Jaddou HY, Ajlouni KM. Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan. Ann Saudi Med. 2008;28(5):346-351.
49. Chan GC. Type 2 diabetes mellitus with hypertension at primary healthcare level in Malaysia: are they managed according to guidelines? Singapore Med J. 2005;46(3):127-131.
50. Khuwaja AK, Rafique G, White F, Azam SI. Macrovascular complications and their associated factors among persons with type 2 diabetes in Karachi, Pakistan - a multi-center study. J Pak Med Assoc. 2004;54(2):60-66.
51. Shera AS, Jawad F, Maqsood A, Jamal S, Azfar M, Ahmed U. Prevalence of chronic complications and associated factors in type 2 diabetes. J Pak Med Assoc. 2004;54(2):54-59.
52. Tariq M, Hadi A, Rahman SU. Metabolic syndrome in type-2 diabetics: an update on the silent epidemic. Rawal Medical Journal. 2010;35(2):201-204.
53. Tzeng TF, Hsiao PJ, Hsieh MC, Shin SJ. Association of nephropathy and retinopathy, blood pressure, age in newly diagnosed type 2 diabetes mellitus. Kaohsiung J Med Sci. 2001;17(6):294-301.
54. Tseng CH. Body mass index and blood pressure in adult type 2 diabetic patients in Taiwan. Circ J. 2007;71(11):1749-1754.
55. Janghorbani M, Amini M. Metabolic syndrome in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors. Metab Syndr Relat Disord. 2007;5(3):243-254.
56. Vikram NK, Misra A, Pandey RM, et al. Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard. Diabetes Nutr Metab. 2003;16(1):32-40.
57. Dhobi GN, Majid A, Masoodi SR, Bashir MI, Wani AI, Zargar AH. Prevalence of hypertension in patients with new onset type 2 diabetes mellitus. J Indian Med Assoc. 2008;106(2):92, 94-98.
58. Tharkar S, Satyavani K, Viswanathan V. Cost of medical care among type 2 diabetic patients with a co-morbid condition - hypertension in India. Diabetes Res Clin Pract. 2009;83(2):263-267.
59. Hassing LB, Hofer SM, Nilsson SE, et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing. 2004;33(4):355-361.
60. Torffvit O, Tencer J, Rippe B. The response to antihypertensive therapy is dependent on renal structural changes. A 5-year prospective study of renal biopsy in type 2 diabetic patients with micro-macroalbuminuria. J Diabetes Complications. 2010;24(6):361-367.
61. Nilsson PM, Cederholm J, Zethelius BR, Eliasson BR, Eeg-Olofsson K, Gudbj Rnsdottir S. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press. 2011;20(6):348-354.
62. Skliros E, Sotiropoulos A, Vasibossis A, et al. Poor hypertension control in Greek patients with diabetes in rural areas. The VANK study in primary care. Rural Remote Health. 2007;7(3):583.
63. Comaschi M, Coscelli C, Cucinotta D, Malini P, Manzato E, Nicolucci A; SFIDA Study Group - Italian Association of Diabetolo-gists (AMD). Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr Metab Cardiovasc Dis. 2005;15(3):204-211.
64. Bacci S, Rizza S, Prudente S, et al. The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. Diabetes. 2011;60(3): 1000-1007.
65. Zoppini G, Verlato G, Leuzinger C, et al. Body mass index and the risk of mortality in type II diabetic patients from Verona. Int J Obes Relat Metab Disord. 2003;27(2):281-285.
66. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, et al. How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabet Med. 2008;25(12):1433-1439.
67. Higgins GT, Khan J, Pearce IA. Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: what lessons have we learned from the UKPDS and DCCT studies? Acta Ophthalmol Scand. 2007;85(7):772-776.
68. Song SH, Hardisty CA. Early onset type 2 diabetes mellitus: a harbinger for complications in later years - clinical observation from a secondary care cohort. QJM. 2009;102(11):799-806.
69. Dehout F, Haumont S, Gaham N, Amoussou-Guenou K, Hermans MP. Metabolic syndrome in Bantu subjects with type 2 diabetes from sub- Saharan extraction: prevalence, gender differences and HOMA hyperbolic product. Diabetes Metab Syndr Clin Res Rev. 2008;2(1): 5-11.
70. Hu G, Sarti C, Jousilahti P, et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke. 2005;36(12):2538-2543.
71. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J. 2007;28(24):3059-3066.
72. Bosevski M, Pemovska G, Bosevska G, Georgievska-Ismail L. Clinical role of estimation metabolic syndrome's components in type 2 diabetic population with symptomatic coronary artery disease - a comparison of two criteria. Med Arh. 2010;64(3):144-146.
73. del Cañizo-Gómez FJ, Moreira-Andrés MN. Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines? Diabetes Res Clin Pract. 2004;65(2):125-133.
74. Agha A, Dillon D, Corbett M, Sreenan S. Target blood pressure for patients with type 2 diabetes is difficult to achieve in the setting of a busy diabetes clinic. Ir J Med Sci. 2003;172(4):168-170.
75. Babej EB, Babe V, Ofrim D, Toadere A. Prevalence and prognostic significance of silent myocardial ischemia in diabetic patients with and without hypertension. Arch Balk Med Union. 2009;44(3):210-214.
76. Suh DC, Kim CM, Choi IS, Plauschinat CA, Barone JA. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004. J Hypertens. 2009;27(9):1908-1916.
77. Foucan L, Deloumeaux J, Donnet JP, et al. Metabolic syndrome components in Indian migrants with type 2 diabetes. A matched comparative study. Diabetes Metab. 2006;32(4):337-342.
78. Jiménez-Corona A, Rojas R, Gómez-Pérez FJ, Aguilar-Salinas CA. Early-onset type 2 diabetes in a Mexican survey: results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010; 52 Suppl 1:S27-S35.
79. Leitão CB, Canani LH, Kramer CK, et al. Blood pressure means rather than nocturnal dipping pattern are related to complications in Type 2 diabetic patients. Diabet Med. 2008;25(3):308-313.
80. Moehlecke M, Leitão CB, Kramer CK, et al. Effect of metabolic syndrome and of its individual components on renal function of patients with type 2 diabetes mellitus. Braz J Med Biol Res. 2010;43(7): 687-693.
81. Wobeto VP, Pinho Pda C, Souza JR, Zaccariotto TR, Zonati Mde F. Haptoglobin genotypes and refractory hypertension in type 2 diabetes mellitus patients. Arq Bras Cardiol. 2011;97(4):338-345. English and Portuguese.
82. Ezenwaka CE, Offah NV Cardiovascular risk in obese and nonobese patients with type 2 diabetes in the West Indies. J Biomed Sci. 2001;8(4): 314-320.
83. Ezenwaka CE, Nwagbara E, Seales D, et al. A comparative study of the prevalence of the metabolic syndrome and its components in type 2 diabetic patients in two Caribbean islands using the new International Diabetes Federation definition. Arch Physiol Biochem. 2007;113(4-5): 202-210.
84. Hermans MP, Amoussou-Guenou KD, Ahn SA, Rousseau MF. Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes. Diabetes Metab Syndr Clin Res Rev. 2010;4(3):150-154.
85. Fasanmade OA, Okubadejo NU. Magnitude and gender distribution of obesity and abdominal adiposity in Nigerians with type 2 diabetes mellitus. Niger J Clin Pract. 2007;10(1):52-57.
86. Ogawa K, Ueda K, Sasaki H, et al. History of obesity as a risk factor for both carotid atherosclerosis and microangiopathy. Diabetes Res Clin Pract. 2004;66 Suppl 1:S165-S168.
87. Marjani A. Prevalence of obesity among type 2 diabetes mellitus in Gorgan (South East of Caspian Sea), Iran. J Chin Clin Med. 2011;6(2):85-92.
88. Bianchi C, Penno G, Malloggi L, et al. Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. Nutr Metab Cardiovasc Dis. 2008;18(1):31-38.
89. Klein S, Allison DB, Heymsfeld SB, et al; Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; American Society for Nutrition; American Diabetes Association. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the ADA. Am J Clin Nutr. 2007;85(5): 1197-1202.
90. Bener A, Zirie M, Al-Rikabi A. Genetics, obesity, and environmental risk factors associated with type 2 diabetes. Croat Med J. 2005;46(2): 302-307.
91. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med. 2006;23(5):516-521.
92. Daousi C, Casson I F, Gill G V, McFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966): 280-284.
93. Hillier TA, Fosse S, Balkau B, Simon D, Eschwège E, Fagot-Campagna A. Weight, the metabolic syndrome, and coronary heart disease in type 2 diabetes: associations among a national French sample of adults with diabetes-the ENTRED study. J Cardiometab Syndr. 2006;1(5):318-325.
94. Ridderstråle M, Gudbjörnsdottir S, Eliasson B, Nilsson PM, Cederholm J; Steering Committee of the Swedish National Diabetes Register (NDR). Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med. 2006;259(3):314-322.
95. Poljicanin T, Pavlić-Renar I, Metelko Z. Obesity in type 2 diabetes: prevalence, treatment trends and dilemmas. Coll Antropol. 2011;35(3): 829-834.
96. Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with Type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications. 2010;24(6): 368-374.
97. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med. 2002;113(7):569-574.
98. Taruni N, Romeo K, Romola P, Brojendro O, David L. Prevalence study of metabolic syndrome in newly detected diabetes patients in RIMS. J Med Soc. 2010;24(1):2-4.
99. Ezenwaka CE, Offah N V. Abdominal obesity in type 2 diabetic patients visiting primary healthcare clinics in Trinidad, West Indies. Scand J Prim Health Care. 2002;20(3):177-182.
100. Wilson C, Gilliland S, Moore K, Acton K. The epidemic of extreme obesity among American Indian and Alaska Native adults with diabetes. Prev Chronic Dis. 2007;4(1):A06.
101. Ravera M, Noberasco G, Re M, et al. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. Nephrol Dial Transplant. 2009;24(5):1528-1533.
102. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11(3):309-317.
103. Reddy KS. Regional case studies - India. Nestle Nutr Workshop Ser Pediatr Program. 2009;63:15-24; discussion 41-46, 259-268.
104. Barquera S, Durazo-Arvizu RA, Luke A, Cao G, Cooper RS. Hypertension in Mexico and among Mexican Americans: prevalence and treatment patterns. J Hum Hypertens. 2008;22(9):617-626.
105. Dorobantu M, Darabont RO, Badila E, Ghiorghe S. Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study. Int J Hypertens. 2010;2010:970694.
106. International Diabetes Federation (IDF). The IDF Worldwide Consensus Definition of the Metabolic Syndrome. Brussels: IDF; 2006. Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_fnal.pdf. Accessed February 14, 2013.
107. Misra A, Chowbey P, Makkar BM, et al; Consensus Group. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163-170.
108. IDF. The global burden [web page on the Internet]. In: IDF Diabetes Atlas. 5th ed. Brussels: IDF; nd. Available from: http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed February 14, 2013.
109. WHO Global Health Observatory Data Repository. Blood pressure: raised blood pressure (SBP $ 140 or DBP $ 90) [database on the Internet]. Geneva: WHO; nd. Available from: http://apps.who.int/gho/data/?theme=main&node=A875#. Accessed February 14, 2013.
110. WHO Global Health Observatory Data Repository. Overweight/ Obesity: obesity (body mass index $30) by country [database on the Internet]. Geneva: WHO; nd. Available from: http://apps.who.int/gho/data/?theme=main&node=A900#. Accessed February 14, 2013.
111. Cheng XB, Hsieh YT, Tu ST, Hsieh MC. Obesity and low target attainment rates in Chinese with type 2 diabetes. Eur J Intern Med. 2012;23(4):e101-e105.
112. DiBonaventura MD, Liu GG, Stankus A. The prevalence and burden of comorbid hypertension and obesity among patients with type 2 diabetes in Urban China. Value Health. 2012;15(7):A664.
113. Feng RN, Zhao C, Wang C, Niu YC, Li K, Guo FC, et al. BMI is strongly associated with hypertension, and waist circumference is strongly associated with type 2 diabetes and dyslipidemia, in northern Chinese adults. J Epidemiol. 2012;22(4):317-323.
114. Hossain MS, Rahaman MZ, Banik S, Sarwar MS, Yokota K. Prevalence of the metabolic syndrome in diabetic patients living in a coastal region of Bangladesh. Int J Pharm Sci Res. 2012;3(8): 2633-2638.
115. Katchunga P, Masumbuko B, Belma M, Kashongwe Munogolo Z, Hermans M P, M'buyamba-Kabangu JR. Age and living in an urban environment are major determinants of diabetes among South Kivu Congolese adults. Diabetes Metab. 2012;38(4):324-231.
116. Frank LK, Heraclides A, Danquah I, Bedu-Addo G, Mock-enhaupt F P, Schulze MB. Measures of general and central obesity and risk of type 2 diabetes in a Ghanaian population. Trop Med Int Health. 2013;18(2):141-151.
117. Berraho M, El Achhab Y, Benslimane A, El Rhazi K, Chikri M, Nejjari C. Hypertension and type 2 diabetes: a cross-sectional study in Morocco (EPIDIAM Study). Pan Afr Med J. 2012;11:52.
118. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3): 293-301.
119. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804-814.
120. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754): 1775-1784.
121. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Washington DC: US Department of Health and Human Services; 2004. Available from: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Accessed February 10, 2013.
122. White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc (2003). 2009;49 Suppl 1:S30-S40.